VitaSpring Biomedical Co., Ltd. has filed its annual report for the fiscal year ended January 31, 2026. The company is in a development stage and has not generated revenue in the past two fiscal years. As of January 31, 2026, the company reported a cash balance of $2,084, total assets of $14,676, and total liabilities of $4,445,244, resulting in a stockholders' deficit of $4,430,568. The company's financial statements have been prepared with substantial doubt about its ability to continue as a going concern within the next twelve months. Operating expenses decreased to $385,411 in fiscal year 2026 from $679,914 in fiscal year 2025. Net loss for fiscal year 2026 was $415,368, an improvement from $774,922 in fiscal year 2025. The company relies on external funding and related-party support, with no committed financing arrangements. A material weakness in internal control over financial reporting was identified due to insufficient segregation of duties and lack of personnel with U.S. GAAP and SEC reporting expertise.